Aquinox Pharmaceuticals, Inc. (AQXP) Cut to Hold at Zacks Investment Research
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “
A number of other analysts have also commented on AQXP. ValuEngine raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Cantor Fitzgerald set a $28.00 price target on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, May 9th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Aquinox Pharmaceuticals has an average rating of “Buy” and an average target price of $19.80.
Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 0.48% during midday trading on Tuesday, hitting $14.44. 34,910 shares of the stock traded hands. Aquinox Pharmaceuticals has a 1-year low of $6.87 and a 1-year high of $19.97. The company’s market capitalization is $338.23 million. The stock has a 50 day moving average of $14.02 and a 200 day moving average of $15.95.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings results on Tuesday, May 9th. The company reported ($0.36) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.15. During the same period last year, the business earned ($0.39) EPS. Equities research analysts predict that Aquinox Pharmaceuticals will post ($2.05) earnings per share for the current fiscal year.
WARNING: This piece of content was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/11/aquinox-pharmaceuticals-inc-aqxp-cut-to-hold-at-zacks-investment-research.html.
In other news, insider David Main sold 15,625 shares of the firm’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $13.26, for a total transaction of $207,187.50. Following the completion of the transaction, the insider now directly owns 77,530 shares in the company, valued at $1,028,047.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.70% of the stock is owned by company insiders.
An institutional investor recently bought a new position in Aquinox Pharmaceuticals stock. Investment Centers of America Inc. bought a new position in Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 10,363 shares of the company’s stock, valued at approximately $172,000. Institutional investors and hedge funds own 98.36% of the company’s stock.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.